<div class="infobox">
<div class="infobox-header">AD Pipeline Overview</div>
<div class="infobox-content">
<table>
<tr><th>Total Programs</th><td>29</td></tr>
<tr><th>Phase 3</th><td>12</td></tr>
<tr><th>Phase 2</th><td>12</td></tr>
<tr><th>Phase 1</th><td>4</td></tr>
</table>
</div>
</div>
<div class="infobox">
<div class="infobox-header">AD Pipeline Overview</div>
<div class="infobox-content">
<table>
<tr><th>Total Programs</th><td>29</td></tr>
<tr><th>Phase 3</th><td>12</td></tr>
<tr><th>Phase 2</th><td>12</td></tr>
<tr><th>Phase 1</th><td>4</td></tr>
</table>
</div>
</div>
This page catalogs companies and their therapeutic programs targeting Alzheimer's Disease. For detailed company profiles, see the Companies Index.
| Company | Drug | Mechanism | Target |
|---------|------|-----------|--------|
| Eisai/Biogen | Lecanemab (LEQEMBI) | Anti-Aβ monoclonal antibody | Amyloid-beta |
| Eli Lilly | Donanemab (KISUNLA) | Anti-Aβ monoclonal antibody | Amyloid-beta |
| Eli Lilly | Remternetug (BBU-384) | Anti-Aβ monoclonal antibody | Amyloid-beta |
| Roche | Gantenerumab (GRADUATE) | Anti-Aβ monoclonal antibody | Amyloid-beta |
| Roche | Crenezumab (CREAD) | Anti-Aβ monoclonal antibody | Amyloid-beta |
| Biogen | Aducanumab (EMERGE) | Anti-Aβ monoclonal antibody | Amyloid-beta |
| Eli Lilly | Solanezumab (EXPEDITION) | Anti-Aβ monoclonal antibody | Amyloid-beta |
| Cassava Sciences | Simufilam (RECOGNIZE) | Filamin A modulator | Filamin A |
| Athira Pharma | NF-043 | HGF/MET activator | MET receptor |
| Company | Drug | Mechanism | Target |
|---------|------|-----------|--------|
| AC Immune | ACI-35 (Lifelong) vaccine | Phospho-tau vaccine | Phospho-tau |
| Prothena | Prasinezumab | Anti-α-synuclein antibody | α-Synuclein |
| Athira Pharma | NF-043 | HGF/MET activator | Neuroprotection |
| Denali | DNL151 | LRRK2 inhibitor | LRRK2 |
| Ionis | IONIS-MAPTx | Antisense oligonucleotide | Tau |
| BlueRock Therapeutics | BLA-01 | Cell therapy | Dopamine |
| Nodthera | NT-0796 | NLRP3 inflammasome inhibitor | Neuroinflammation |
| Axsome Therapeutics | AXS-060 | Sigma-1 receptor agonist | Neuroprotection |
| ProMIS Neurosciences | PMN310 | Anti-Aβ oligomer antibody | Amyloid-beta oligomers |
| Acumen Pharmaceuticals | ACU193 | Anti-Aβ oligomer antibody | Amyloid-beta oligomers |
| INmune Bio | XPro1595 | TNF inhibitor | Neuroinflammation |
| Alector | Latozinemab (AL101) | Progranulin enhancer | TREM2](/proteins/trem2) |
| Lexeo Therapeutics | LX1001 | AAV-APOE4 gene therapy | APOE4 |
| Company | Drug | Mechanism | Target |
|---------|------|-----------|--------|
| Merck | MK-2514 | GLP-1 receptor agonist | Neuroprotection |
| Novartis | BIM-42788 | Tau aggregation inhibitor | Tau |
| AbbVie | ABBV-916 | Anti-Aβ antibody | Amyloid-beta |
| Pfizer | PF-06423879 | BACE inhibitor | Amyloid-beta |
This section lists all companies with AD-related programs in the NeuroWiki database.
| Company | Focus Area | Page |
|---------|------------|------|
| AbbVie | Anti-amyloid, tau | Link |
| Amgen | Anti-amyloid, tau | Link |
| AstraZeneca plc | Anti-amyloid, tau | Link |
| Bayer | Anti-amyloid, tau | Link |
| Biogen | Anti-amyloid, tau | Link |
| Bristol Myers Squibb | Anti-amyloid, tau | Link |
| Eisai Co., Ltd. | Anti-amyloid, tau | Link |
| Eli Lilly | Anti-amyloid, tau | Link |
| GlaxoSmithKline plc (GSK) | Anti-amyloid, tau | Link |
| H. Lundbeck A/S | Anti-amyloid, tau | Link |
| Merck | Anti-amyloid, tau | Link |
| Novartis | Anti-amyloid, tau | Link |
| Pfizer Inc | Anti-amyloid, tau | Link |
| Regeneron Pharmaceuticals | Anti-amyloid, tau | Link |
| Roche | Anti-amyloid, tau | Link |
| Sanofi | Anti-amyloid, tau | Link |
| Takeda Pharmaceutical Company | Anti-amyloid, tau | Link |
| UCB Pharma | Anti-amyloid, tau | Link |
| Galapagos NV | Anti-amyloid, tau | Link |
| Shionogi & Co., Ltd. | Anti-amyloid, tau | Link |
| Company | Focus Area | Page |
|---------|------------|------|
| AC Immune SA | Various | Link |
| Acumen Pharmaceuticals | Various | Link |
| Alnylam Pharmaceuticals | Various | Link |
| Anavex Life Sciences | Various | Link |
| Annovis Bio, Inc. | Various | Link |
| AriBio | Various | Link |
| Athira Pharma, Inc. | Various | Link |
| Axsome Therapeutics, Inc. | Various | Link |
| BlueRock Therapeutics | Various | Link |
| Axial Therapeutics | Various | Link |
| Cognition Therapeutics | Various | Link |
| Cassava Sciences, Inc. | Various | Link |
| Cerevel Therapeutics | Various | Link |
| Denali Therapeutics | Various | Link |
| Inhibrx | Various | Link |
| INmune Bio, Inc. | Various | Link |
| Ionis Pharmaceuticals | Various | Link |
| Lexeo Therapeutics | Various | Link |
| Life Biosciences | Various | Link |
| Neumora Therapeutics | Various | Link |
| Nodthera Ltd. | Various | Link |
| Pinteon | Various | Link |
| ProMIS Neurosciences | Various | Link |
| Prothena Corporation plc | Various | Link |
| Vaxxinity, Inc. | Various | Link |
| Wave Life Sciences | Various | Link |